Rivastigmine treatment as an add‑on to antipsychotics in patients with schizophrenia and cognitive deficits

Abstract

Rivastigmine treatment did not appear to enhance cognition in SZ patients with important cognitive impairments. This finding needs to be interpreted with care and requires substantiation with larger sample size studies with patients treated with cognitive enhancer for longer periods.